Evonile Pharma (500672) Q2 25/26 earnings summary

Executive summary

• Q2 FY26 revenue from operations was 903.3 million; profit for the period was 242.2 million, versus 871.0 million and 204.1 million in Q2 FY25.

• H1 FY26 revenue was 1,778.8 million and profit was 518.4 million, versus 1,793.9 million and 461.5 million in H1 FY25.

Financial highlights

• Q2 FY26 total income was 997.3 million, including 94.0 million of other income; Q2 FY25 total income was 974.2 million.

• Q2 FY26 profit before tax was 326.5 million versus 275.6 million YoY; total expenses were 670.8 million versus 698.6 million.

• H1 FY26 profit before tax was 698.7 million versus 612.4 million YoY; total expenses were 1,280.2 million versus 1,388.8 million.

• H1 FY26 total income was 1,978.9 million versus 2,001.2 million in H1 FY25; other income was 200.1 million versus 207.3 million.

Segment performance

• Operations comprise one business segment: Pharmaceuticals Business.